The Global B-cell Maturation Antigen (BCMA) Targeted Therapies Market, by product type (CAR-T cell, bispecific antibodies, and antibody drug conjugates), and by indication (acute lymphoblastic leukemia, and multiple myeloma) has potential products in pipeline. Increasing number of BCMA targeted therapies in pipeline and increasing prevalence of multiple myeloma are expected to favor growth of the B-cell maturation antigen (BCMA) targeted therapies market worldwide. Increasing recurrence of multiple myeloma has been a major obstacle. According to the National Cancer Institute, in 2016, around 75,000 patients globally were recorded to be suffering from relapsed or refractory multiple myeloma, with a relative survival rate of 5 years. According to American Cancer Society, as of 2017, around 30,280 multiple myeloma cases are estimated to be diagnosed, out of which around 12,590 deaths are estimated to occur. Multiple myeloma (MM) is the second most common hematological malignancy in the U.S. and European countries.
According to American Cancer Society, in the U.S. the lifetime risk of contracting multiple myeloma is 1 in 143 (0.7%). B-cell maturation antigen (BCMA), is a cell surface protein that is expressed on the malignant plasma cells. This cell surface protein has emerged as a very selective antigen to be targeted for the treatment of multiple myeloma. B-cell maturation antigen possess co-immunoprecipitation property with a master transcription factor (IRF-4) are mediated for myeloma cell survival. This suggests the potential effect of BCMA in oncogenesis, making it a choice of preference for multiple myeloma treatment. Thus, rise in number of multiple myeloma cases and development of novel BCMA therapy for the treatment of multiple myeloma provides lucrative opportunities for the market players. Adoption of BCMA targeted therapies is expected increase, as patients undergoing chemotherapy and radiation therapy are prone to recurrence of cancer. Browse through 130 Pages and an in-depth TOC on ‘B-cell Maturation Antigen (BCMA) Targeted Therapies, by Product type (Antibody Drug Conjugates, CAR-T Cells, and Bispecific Antibodies), by Indication (Acute Lymphoblastic Leukemia and Multiple Myeloma), and by Region
To know the latest trends and insights prevalent in the B-cell maturation antigen (BCMA) targeted therapies market, click the link below: https://www.coherentmarketinsights.com/market-insight/bcma-targeted-therapies-market-190
According to the Cancer Research U.K., as of 2014, myeloma is estimated to be the 18th most common cancer in the U.K., with around 15 new cases reported every day. Myeloma rates are projected to grow by 11% or 12 cases per 100,000 people by 2035. According to the National Center for Biotechnology Information (NCBI), in 2014, multiple myeloma represented 8.2% of all blood cancers in Africa. Market players are majorly investing in research and development of novel multiple myeloma therapies, which include chimeric antigen receptor T cells, antibody-drug conjugate, and bispecific antibodies. Preclinical and clinical trial results on these therapies have demonstrated potential benefits. Key player in the market such as Glaxosmithkline Plc. is developing an antibody drug conjugate for the treatment of relapsed/refractory multiple myeloma and other advanced hematologic malignancies expressing BCMA, whereas Bluebird Bio, Inc. is actively developing an anti-BCMA CAR-T cell drug product to treat relapsed and/or refractory multiple myeloma. Boehringer Ingelheim GmbH is performing clinical trials for relapsed and/or refractory multiple myeloma patients using bispecific antibody.
Key Takeaways of the Market: